LEADER 05363nam 2200649Ia 450 001 9910139879003321 005 20170810175142.0 010 $a1-282-34608-3 010 $a9786612346088 010 $a0-470-50816-7 010 $a0-470-50815-9 035 $a(CKB)1000000000807100 035 $a(EBL)468790 035 $a(OCoLC)502012584 035 $a(SSID)ssj0000294347 035 $a(PQKBManifestationID)11195941 035 $a(PQKBTitleCode)TC0000294347 035 $a(PQKBWorkID)10312123 035 $a(PQKB)10207252 035 $a(MiAaPQ)EBC468790 035 $a(PPN)243326181 035 $a(EXLCZ)991000000000807100 100 $a20090206d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug design of zinc-enzyme inhibitors$b[electronic resource] $efunctional, structural, and disease applications /$fedited by Claudiu T. Supuran, Jean-Yves Winum 210 $aHoboken, NJ $cJohn Wiley & Sons$dc2009 215 $a1 online resource (1072 p.) 225 1 $aWiley Series in Drug Discovery and Development ;$vv.14 300 $aDescription based upon print version of record. 311 $a0-470-27500-6 320 $aIncludes bibliographical references and index. 327 $aDRUG DESIGN OF ZINC-ENZYME INHIBITORS; CONTENTS; PREFACE; CONTRIBUTORS; PART I INTRODUCTION; 1. Introduction to Zinc Enzymes as Drug Targets; PART II DRUG DESIGN OF CARBONIC ANHYDRASE INHIBITORS AND ACTIVATORS; 2. Carbonic Anhydrases as Drug Targets: General Presentation; 3. Zinc Binding Functions in the Design of Carbonic Anhydrase Inhibitors; 4. X-Ray Crystallography of Carbonic Anhydrase Inhibitors and Its Importance in Drug Design; 5. Antiglaucoma Carbonic Anhydrase Inhibitors as Ophthalomologic Drugs 327 $a6. Diuretics with Carbonic Anhydrase Inhibitory Activity: Toward Novel Applications for Sulfonamide Drugs7. Drug Design of Carbonic Anhydrase Inhibitors as Anticonvulsant Agents; 8. Carbonic Anhydrase Inhibitors Targeting Cancer: Therapeutic, Immunologic, and Diagnostic Tools Targeting Isoforms IX and XII; 9. Fluorescent- and Spin-Labeled Sulfonamides as Probe for Carbonic Anhydrase IX; 10. Drug Design of Antiobesity Carbonic Anhydrase Inhibitors; 11. Dual Carbonic Anhydrase and Cyclooxygenase-2 Inhibition 327 $a12. Advances in the Inhibitory and Structural Investigations on Carbonic Anhydrase Isozymes XIII and XV13. Mechanism and Inhibition of the ?-Class and ?-Class Carbonic Anhydrases; 14. Fungal and Nematode Carbonic Anhydrases: Their Inhibition in Drug Design; 15. Crystallographic Studies on Carbonic Anhydrases from Fungal Pathogens for Structure-Assisted Drug Development; 16. Malaria Parasite Carbonic Anhydrase and Its Inhibition in the Development of Novel Therapies of Malaria; 17. Inhibitors of Helicobacter pylori ?- and ?-Carbonic Anhydrases as Novel Drugs for Gastroduodenal Diseases 327 $a18. QSAR of Carbonic Anhydrase Inhibitors and Their Impact on Drug Design19. Selectivity Issues in the Design of CA Inhibitors; 20. Bicarbonate Transport Metabolons; 21. Metal Complexes of Sulfonamides as Dual Carbonic Anhydrase Inhibitors; 22. Drug Design Studies of Carbonic Anhydrase Activators; PART III DRUG DESIGN OF MATRIX METALLOPROTEINASE INHIBITORS; 23. Matrix Metalloproteinases: An Overview; 24. MMP Inhibitors Based on Earlier Succinimide Strategies: From Early to New Approaches; 25. Drug Design of Sulfonylated MMP Inhibitors; 26. ADAMs and ADAMTs Selective Synthetic Inhibitors 327 $a27. QSAR Studies of MMP InhibitorsPART IV DRUG DESIGN OF BACTERIAL ZINC PROTEASE INHIBITORS; 28. Bacterial Zinc Proteases as Orphan Targets; 29. Botulinus Toxin, Tetanus Toxin, and Anthrax Lethal Factor Inhibitors; 30. Clostridium histolyticum Collagenase Inhibitors in the Drug Design; 31. Other Bacterial Zinc Peptidases as Potential Drug Targets; PART V DRUG DESIGN STUDIES OF OTHER ZINC-CONTAINING ENZYMES; 32. Angiotensin Converting Enzyme (ACE) Inhibitors; 33. P-III Metalloproteinase (Leucurolysin-B) from Bothrops leucurus Venom: Isolation and Possible Inhibition 327 $a34. CaaX-Protein Prenyltransferase Inhibitors 330 $aBrings together functional and structural informationrelevant to the design of drugs targeting zinc enzymes The second most abundant transition element in living organisms, zinc spans all areas of metabolism, with zinc-containing proteins offering both established and potential drug targets. Drug Design of Zinc-Enzyme Inhibitors brings together functional and structural information relevant to these zinc-containing targets. With up-to-date overviews of the latest developments field, this unique and comprehensive text enables readers to understand zinc enzymes and evaluate them 410 0$aWiley Series in Drug Discovery and Development 606 $aZinc enzymes$xInhibitors$xTherapeutic use 606 $aDrugs$xDesign 615 0$aZinc enzymes$xInhibitors$xTherapeutic use. 615 0$aDrugs$xDesign. 676 $a615/.19 701 $aSupuran$b Claudiu T.$f1962-$0942469 701 $aWinum$b Jean-Yves$0942470 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139879003321 996 $aDrug design of zinc-enzyme inhibitors$92126805 997 $aUNINA